The objective of the study was to assess safety and efficacy of TAVR in patients with bicuspid aortic valve stenosis and low surgical risk with a follow-up of 10 years. The primary safety endpoint was all-cause mortality or disabling stroke at 30 days; the primary efficacy endpoint was device success. The study was performed in high-volume experienced centres, which recommended annular sizing and strongly encouraged pre-TAVR balloon dilatation (91.3%). The study included 150 patients with bicuspid aortic valve anatomy confirmed by multi-slice CT. They were either symptomatic or asymptomatic and their predicted risk of mortality was <3%. Mean age of the patients was 70 years, and 147 individuals completed follow-up.
At 30 days after the procedure, 1.3% of patients had died (1 patient was excluded due to coronary obstruction), and 3.3% of patients had experienced a non-disabling stroke. The device’s success rate at 30 days was 95.3%. Valve haemodynamics were centrally adjudicated by a core echocardiographic laboratory; mean aortic valve gradient was 7.6 mmHg and the effective orifice area was 2.3 cm2. Mild aortic regurgitation occurred in 40.4% of patients. However, no moderate or severe aortic regurgitation was seen in this population. In this study, TAVR was shown to be safe and effective. However, Dr Ramlawi concluded, the choice between TAVR and surgery remains a complicated one and should be based on a multidisciplinary heart team discussion that includes anatomic, clinical, and patient social factors.
- Ramlawi B, et al. Abstract 405-10. ACC/WCC 28-30 March 2020.
Posted on
Previous Article
« ES-SCLC: pembrolizumab KEYNOTE-604 data Next Article
Quit smoking: vaping + counselling helps »
« ES-SCLC: pembrolizumab KEYNOTE-604 data Next Article
Quit smoking: vaping + counselling helps »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 8, 2020
Renal denervation better than sham for blood pressure
September 8, 2020
Radial artery best for second bypass
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com